Nikol S
Chefärztin Klinische und Interventionelle Angiologie, Asklepios Klinik St.Georg, Lohmühlenstr. 5, 20099 Hamburg.
Dtsch Med Wochenschr. 2011 Apr;136(14):672-4. doi: 10.1055/s-0031-1274561. Epub 2011 Mar 29.
The world-wide largest angiogenesis gene therapy trial in 525 patients suffering from critical limb ischemia and treated with the non-viral gene construct for fibroblast growth factor (NV1FGF) or placebo was negative for all endpoints. Also, stem cell or progenitor cell therapy did no reveal clinical benefit in patients with peripheral artery disease. Data from large randomized placebo-controlled are still not available.
在一项针对525例严重肢体缺血患者的全球最大规模血管生成基因治疗试验中，患者接受成纤维细胞生长因子非病毒基因构建体（NV1FGF）或安慰剂治疗，所有终点结果均为阴性。此外，干细胞或祖细胞疗法在周围动脉疾病患者中未显示出临床益处。目前仍没有来自大型随机安慰剂对照试验的数据。
